Work

Interim results from a first-in-human study with AMG102, a fully human monoclonal antibody that neutralizes hepatocyte growth factor (HGF), the ligand to c-Met receptor, in patients (pts) with advanced solid tumors

Year: 2007

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2007.25.18_suppl.3551

Authors: M. S. Gordon, D. S. Mendelson, C. Sweeney, N. Erbeck, R. Patel, T. Kakkar, L. Yan, S. G. Eckhardt, L. Gore

Institutions: Amgen (United States), University of Colorado Cancer Center, Pinnacle Oncology Hematology, Indiana University Indianapolis

Language: English

Topic: Monoclonal and Polyclonal Antibodies Research

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3010187320

Cites:

Cited by: 23

Related to: 10